Rx patent monopoly and Lizzo TM win

Please join us Monday, March 6, 2023 where we will discuss Rx patent monopoly issues and Lizzo's TM win.  Specific case discussions will include: AbbVie Rx Patent Monopoly Strategy Against Biosimilars - AbbVie makes Humera for arthritis and extended its monopoly for 7 years past the 2016 expiration date of its basic patent on the [...]

By |2023-11-09T13:31:44-08:00March 2nd, 2023|Antitrust, FDA, Patent, Trademark, TTAB, monopoly|0 Comments

SoCal IP Institute :: July 1, 2013 :: The Line Between Patent and Antitrust &Undue Experimentation Under 35 U.S.C. 112

Our weekly SoCal IP Institute meeting on Monday, July 1, 2013 will be a discussion of a recent Supreme Court case regarding the line between patent and antitrust and a Federal Circuit decision on enablement. Brief synopses of the cases appear below. FTC v. Actavis, Inc., Case No. 12-416 (U.S.  June 17, 2013) (available here).  [...]

By |2013-06-28T22:01:26-07:00June 28th, 2013|Antitrust, Patent, Statutory Subject Matter, Enablement|0 Comments

SoCal IP Institute :: November 26, 2012 :: Overcoming Prima Facie Obviousness and Standing

We will be discussing two Federal Circuit cases during our weekly SoCal IP Institute meeting on Monday, November 26, 2012. Brief synopses are presented below. Transocean Offshore Deepwater Drilling, Inc. v. Maersk Drilling USA, Inc., Case No. 2011-1555 (Fed. Cir. November 15, 2012) (attached). This case involves a patent for offshore drilling technology that allows [...]

SoCal IP Institute :: November 28, 2011 :: Antitrust & Patent Law and Costs in Patent Litigation

We will be discussing one California antitrust case with patent law implications and one patent case pertaining to costs in litigation during our weekly SoCal IP Institute meeting on Monday, November 28, 2011. Brief synopses are presented below. In re Cipro Cases I & II, D056361 (Cal. App. Oct. 31, 2011) (attached). On appeal, Plaintiffs [...]

By |2011-11-28T03:03:52-08:00November 28th, 2011|Patent, ANDA, Inequitable Conduct, Antitrust|0 Comments
Go to Top